Belumosudil (KD025)

DRUG3 trials

Sponsors

Kadmon, a Sanofi Company

Conditions

Chronic Graft-versus-host-diseaseDiffuse Cutaneous Systemic SclerosisGraft vs Host DiseaseSystem; Sclerosis

Phase 2

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

CompletedNCT02841995

Kadmon, a Sanofi CompanyGraft vs Host Disease

Start: 2016-09-15End: 2022-05-12Updated: 2023-06-28

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

TerminatedNCT03640481

Kadmon, a Sanofi CompanyChronic Graft-versus-host-disease

Start: 2018-10-11End: 2023-12-11Updated: 2024-12-12

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

TerminatedNCT03919799

Kadmon, a Sanofi CompanyDiffuse Cutaneous Systemic Sclerosis, System; Sclerosis

Start: 2019-06-26End: 2023-02-17Updated: 2023-08-30

Related Papers

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study

Blood2025-11-03

Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Blood Advances2025-05-013 citations

Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies

Transplantation and Cellular Therapy2025-05-011 citations

Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study

Lara D. Veeken2025-03-143 citations

Characterization of Real-World Chronic Graft-Versus-Host-Disease Patients Receiving Belumosudil

Blood2022-11-15

Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.

2022-07-0117 citations

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood2021-07-15292 citations